The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pierre Fabre (Inst)
Patents, Royalties, Other Intellectual Property - TRIM24 regulation pending patent (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Yin Wu
Consulting or Advisory Role - E15VC
 
Oliver Bechter
No Relationships to Disclose
 
Daniel Brungs
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - MSD
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; Immunocore; MSD Oncology; Pierre Fabre; Sanofi; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Hanna Eriksson
Honoraria - MSD (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst)
Consulting or Advisory Role - MSD (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst)
Research Funding - Skyline Diagnostics (Inst)
 
Peter Mohr
Honoraria - Bristol-Myers Squibb; Delcat; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma Advanced Research Company
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis Deutschland LTd (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sun Pharma
 
Rossanna Pezo
Honoraria - Gilead Sciences; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer/EMD Serono; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Gilead Sciences; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche; Sanofi
Speakers' Bureau - Novartis Canada Pharmaceuticals Inc
Research Funding - Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Egle Ramelyte
Honoraria - BMS GmbH & Co. KG; Galderma; Lilly; MSD; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Kyowa Kirin International; Sanofi/Regeneron
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Sanofi/Regeneron
Research Funding - Amgen (Inst); Sanofi/Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Contribution to UpToDate chapter update for Superficial acitic porokeratosis.
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Sanofi
 
Bernardo Rapoport
Consulting or Advisory Role - Acino Pharma South Africa; Astellas Pharma; Astra-Zeneca South Africa; Eisai South Africa; Janssen; Lilly South Africa; Merck; Novartis South Africa; Pfizer South Afrtica; Roche; Sandoz/Hexal; Takeda South Africa
Speakers' Bureau - Acino Pharma South Africa; Astellas Pharma; AstraZeneca; Eisai South Africa; Janssen Oncology South Africa; Lilly South Africa; MSD Oncology; Novartis South Africa; Pfizer South Africa; Roche; Sandoz/Hexal; Takeda
 
Gareth Rivalland
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; MSD
Travel, Accommodations, Expenses - Roche
 
Amitesh Roy
Honoraria - BeiGene; Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - MSD Oncology; Roche
Research Funding - Merck Serono (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
 
Mizuho Fukunaga-Kalabis
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Geetha Krishna Kaza
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Yayan Zhang
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Etah Kurland
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Alexander Eggermont
Stock and Other Ownership Interests - IO Biotech; Sairopa; Skyline Diagnostics
Honoraria - Agenus; Bioinvent; BioNTech; Brenus Pharma; Catalym; Ellipses Pharma; Genoway; GlaxoSmithKline; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Consulting or Advisory Role - Bioinvent; BioNTech; Brenus Pharma; Catalym; Ellipses Pharma; Genoway; GlaxoSmithKline; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD